NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis reported today that its first-half 2016 revenues fell 7 percent year over year on lower collaboration revenues.

The firm reported total revenues of €6.1 million ($6.9 million) versus €6.6 million for the first half of 2015. Its product sales jumped 63 percent to €2.7 million from €1.7 million, due to a 314 percent year-over-jump increase in cartridge sales. Sales for its Idylla molecular diagnostics systems were down 21 percent to €988,000 from €1.2 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Aug
09

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.